Deep Dive

Market Access

illustration of person walking from above

Chasing the holy grail of value-based healthcare

Patients, healthcare professionals, payers, and other stakeholders can have vastly different views on the value of a particular product, often resulting in a struggle between prioritising a

Market Access

Rare diseases: the urgent need for health equity and acceler...

Rare diseases are complex, but the need is urgent. Alexion’s Eunice Alvazzi discusses the shared responsibility in achieving access to innovation in rare diseases

Market Access

The biosimilars dance: How drugmakers game the US patent sys...

When the primary patent on a blockbuster drug expires, affordable generic or biosimilar competition is expected to balance the market, offering relief to patients who could not afford the h

Market Access

Overcoming AMR market failure: Three start-up stories

Slowly but surely, the world’s antibiotics are becoming less effective as disease-causing bacteria evolve into drug-resistant “superbugs”.

Market Access

The UK vs. superbugs: Combatting AMR on the homefront

AMR, or antimicrobial resistance, is never far from the conversation these days.

Market Access

Deep Dive: Market Access 2024

In this edition of Deep Dive, Unpacking complex choreography in the biologics patent dance, Alexion examines the urgent need for accelerated access programmes for rare disease treatments, and Putna

Chasing the holy grail of value-based healthcare

Rare diseases: the urgent need for health equity and acceler...

The biosimilars dance: How drugmakers game the US patent sys...

Overcoming AMR market failure: Three start-up stories

The UK vs. superbugs: Combatting AMR on the homefront

Deep Dive: Market Access 2024

Tenpoint eyes presbyopia drug launch after FDA nod

How to meet your physicians where they are online

Deep Dive

Editor's Picks